Single Dose of Tranexamic Acid and Blood Loss, in Elderly Patients With Hip Fracture

• Status: Unknown status
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to investigate the hypothesis that single dose of tranexamic acid (TXA) preoperatively will lower blood loss and transfusion rate in elderly patients with hip fractures (intertrochanteric or Subcapital), that will be treated with intramedullary nailing and cemented hemiarthroplasty respectively. After application of inclusion and exclusion criteria, patients will be randomized in two groups. Group 1 will include patients that receive preoperatively single dose of TXA (15mg/kg) and Group 2 will include patients that receive normal saline (control group).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National and Kapodistrian University of Athens
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Consecutive elderly patients (age >75 yo) undergoing hip fracture surgery for a stable or unstable intertrochanteric hip fracture with the insertion of a short intramedullary nail (IMN) as well as patients treated surgically with cemented hemiarthroplasty for acute femoral neck (subcapital) hip fracture.

Exclusion Criteria:

• Any contraindication for tranexamic acid

• Multiple fractures

• Requirement for anticoagulant therapy that could not be stopped.

• Ongoing thromboembolic event

• reduced kidney function

• malignancy,

• pathological fracture

• previous operation on the affected hip

• Active coronary artery disease (event in the past 12 months).